Lipella Pharmaceuticals Inc (LIPO) 銘柄情報

Zzzz $3 smaller float + 8%!

Lipo should be 10 usd before 2025

thanks but I was sleeping....


zzzzzzz

.57 + 41%

.53+ 33% Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform

Source: GlobeNewswire Inc.

Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company focused on developing therapies for serious diseases with unmet medical needs, today announced the receipt of a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for its proprietary liposomal drug delivery platform. The patent application, U.S. Patent No. 17/829,960, titled "Delivery of Agents Using Metastable Liposomes," covers key innovations in Lipella’s platform technology for delivering therapeutic agents via liposome-based vehicles.
The patent allows claims that cover Lipella’s method for using metastable liposomes to deliver a variety of therapeutic agents, including the company’s lead assets, LP-10 and LP-310. This breakthrough technology enables precise, targeted delivery, improving the safety and efficacy of treatments across multiple therapeutic areas, including oncology, cancer survivorship, and immunotherapy.

Dr. Michael Chancellor, Chief Medical Officer of Lipella Pharmaceuticals, commented, "The allowance of this patent is a significant milestone for Lipella as it strengthens our intellectual property portfolio and supports our ongoing efforts to advance therapies for conditions such as hemorrhagic cystitis and oral lichen planus. Our liposomal drug delivery system offers a safer and more effective means of administering therapeutics like tacrolimus by targeting disease sites directly and minimizing the systemic side effects typically associated with these treatments."

This newly allowed patent provides broad intellectual property protection for Lipella’s drug delivery platform, which optimizes delivery to epithelial tissues such as those lining the mouth, bladder, colon, esophagus, vagina, and urethra. It extends market exclusivity and strengthens Lipella’s competitive position, particularly for its two lead clinical assets currently in Phase 2 trials. With additional patents covering the company's formulations in the U.S., Australia, and Canada until 2035, Lipella is poised for further growth and development as it continues to advance its clinical pipeline.

About Lipella’s Lead Clinical Assets: LP-10 and LP-310

LP-10 is a liposomal formulation of tacrolimus designed for intravesical administration to treat hemorrhagic cystitis (HC), a rare but severe condition characterized by bleeding from the bladder. LP-10 has shown promising safety and efficacy results in a multicenter Phase 2a trial, where it improved urinary symptoms in patients. The FDA has granted Orphan Drug Designation to LP-10 for the treatment of moderate to severe HC, further underscoring its potential to address this critical unmet need. A Phase 2b multicenter placebo-controlled trial is ready to begin.
LP-310 is an innovative oral rinse formulation of LP-10, designed to treat oral lichen planus (OLP), a chronic autoimmune disease affecting the mucous membranes of the mouth. LP-310 offers a promising new approach to treating OLP, which affects millions of Americans and currently lacks an approved pharmacotherapy. A Phase 2a multicenter trial is underway with anticipated top-line data by year-end and trial completion by mid-2025.
About Hemorrhagic Cystitis (HC)
Hemorrhagic cystitis is a serious condition often resulting from radiation therapy or chemotherapy, marked by severe bleeding in the bladder. With no FDA-approved drug treatments available, LP-10 is positioned to become a breakthrough therapy for patients suffering from this debilitating condition.

About Oral Lichen Planus (OLP)
Oral lichen planus is a chronic autoimmune disease that causes inflammation and lesions in the oral mucosa. It can lead to significant discomfort, scarring, and increased risk of oral cancer. Despite affecting six to seven million people in the U.S., there are no approved treatments, and current therapies offer only symptomatic relief.

Hop on board pump time .52 +’32%

LIPO............................https://stockcharts.com/h-sc/ui?s=LIPO&p=W&b=5&g=0&id=p86431144783

https://x.com/prism_mediawire/status/1838551573447754079

Give me some liposuction and pump me up

LIPO new 52 low

LIPO new 52

agree but the market doesnt *NHOD*

lol bounced out garbage geeezzzz

Churning good bounce coming

only initiates Phase 2a Trial
where is the big news ?

is just to collect money

Halted!, in at average .90, easily a 3$ stock here $$$$$$

God Bless LIPO God Bless RNAZ

Ahhhhh chew. Bless me

Don’t blink

Golf clap

LIPO...............................https://stockcharts.com/h-sc/ui?s=LIPO&p=W&b=5&g=0&id=p86431144783

LIPO NEWS https://www.globenewswire.com/news-release/2024/07/29/2920081/0/en/Lipella-Pharmaceuticals-Initiates-Phase-2a-Trial-for-LP-310-in-Oral-Lichen-Planus-Enrolls-First-Patients.html

LIPO .80s now cash out time

https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri

https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation

You made me feel old, then i remembered my grandchildren
541,000 LIPO shares traded down 1.9%
Wow normally low volume
J A G X had a lot of volume too 380 mill
Pharmaceuticals are hot

https://twitter.com/StocksGambino/status/1764482368113410078

Roll the dice, gramps you can’t take it with you

This doesn’t trade many shares.
Volume is coming

LIPO under $2

Heading to FDA phase II trial. Long ways to go before FDA phase III approval for marketplace.

Shares of Lipella Pharmaceuticals Inc. (LIPO) rocketed 52.2% higher in very active tracing Friday, after the Pittsburgh-based biotechnology company's investigational new drug application for its oral lichen planus treatment was approved by the U.S. Food and Drug Administration. Trading volume in the stock, which was the best performer on the major U.S. exchanges, blasted higher to 30.7 million shares, compared with the full-day average of about 6,400 shares. The stock has soared 150% in the three days since it last closed below the $1 mark, and has run up 164% amid a six-day winning streak. as Lipella described, OLP is a chronic, inflammatory autoimmune oral muscosal disease. It is a "highly morbid" condition with malignant potential that affects between 1% and 4% of the world population. Lipella's stock has now gained 18.6% over the past three months, but was still 57% below its initial public offering price of $5.75; the company went public on Dec. 20.

-Tomi Kilgore

For more from MarketWatch: http://www.marketwatch.com/newsviewer

Early Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc

Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus

That's it for me, folks!
Went much longer than usual but I have had a terrific day-following a bad day yesterday.
Hit on LIPO news today. Was positioned for the good pop. What a difference a day can make!
Have to drive across the mountain, now. Go do inventory at a shop open late. Then deliver there tomorrow.

LIPO Quote
AS OF 3/16/2023 3:16PM ET

$2.54
+$0.71 (+38.798%)

Volume
22,990,230
90 Day Avg. Vol.
564,085
Open
$2.77
Previous Close 03/15/2023
$1.83

https://stockcharts.com/h-sc/ui?s=LIPO

LIPO NEWS https://finance.yahoo.com/news/lipella-pharmaceuticals-successfully-completes-phase-123000776.html


Hemorrhagic cystitis is a medical condition that occurs when your urinary bladder lining becomes inflamed and bleeds. Your bladder is a muscular sac in your pelvis that stores urine before it's released from your body. Hemorrhagic means bleeding, and cystitis is inflammation of the bladder

Lipella Pharmaceuticals’ (NASDAQ:LIPO – Get Rating) quiet period will expire on Monday, January 30th. Lipella Pharmaceuticals had issued 1,217,391 shares in its IPO on December 20th. The total size of the offering was $6,999,998 based on an initial share price of $5.75. During Lipella Pharmaceuticals’ quiet period, insiders and underwriters involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

65,502 failure to deliver from 1-13 ,wow $300,000@$3.00pps ,insane margin call,shorts better cover now,at ask would put LIPO over $100pps right now ,set my sell at $150.00 just in case

.05 spread,jumping .10-.50 today,no toxic debt or naked short on this newie,after market and pre-mkt tomorrow could gap LIPO multi$,gotta love low float newies

35Xs ave vol,big pre mkt today 1st sign of life since ticker started,now gap filled,charting predictable,appears something coming and float locked up @zero/restricted borrow,436% fee

zero borrow,no shares to short,squeeze em babe!!!!

Shares Outstanding 5.74M,Shares Float 3.77M,Institutional Ownership 6.96%,Insider Ownership 34.42%,Short Float 6.25%, 235,322 shares short

LIPO, Nice day here so far. Thanks for the heads up Hanibal.

$LIPO: Niceeeeeeeeee bounce here....... now 3.80


Came off the bottom.................. nice mercy bounce there from $3 at the open

GO $LIPO